Georg-august-universitat Gottingen Stiftung Offentlichen Rechts, Universitatsmedizin

Synaptic Systems Gesellschaft Für Neurobiologische Forschung, Entwicklung Und Produktion Mbh

Oliver Wirths

Thomas Bayer

Henrik Martens

Christian Erck

The present invention describes a novel transgenic mouse model for the common sporadic form of Alzheimer's disease. More particularly, the invention relates to a nucleotide sequence encoding A&#x3b2; 4-42 in functional linkage with at least a promoter, signal peptide sequence and a polyadenylation signal sequence, a cell and a transgenic non-human animal comprising said nucleotide sequence, and their respective use in screening methods.

Transgenic mouse model expressing amyloid &#x3b2; 4-42 peptide

The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated A&#x3b2; starting with pyroglutamate (A&#x3b2;&#x3c1;E), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing A&#x3b2; oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056. Further, the invention provides a method of inhibiting the formation or the seeding effect of said A&#x3b2;&#x3c1;E oligomers, and a method for identifying agents useful in the treatment and/or prevention of an amyloid-related disorder as well as methods of diagnosing a subject suspected of suffering from a disease associated with amyloidogenesis and/or amyloid plaque formation and to methods of monitoring the efficacy of a treatment of a disease associated with amyloidogenesis and/or amyloid-plaque formation characterized by the presence of A&#x3b2; oligomers in a subject.

Growing community of inventors

Friedland, Germany

Oliver Wirths